Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 20 2024 - 3:05PM
UK Regulatory
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare
Conference
Nyxoah to Participate in the Piper
Sandler 36th Annual
Healthcare Conference
Mont-Saint-Guibert, Belgium – November
20, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext
Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a
medical technology company that develops breakthrough treatment
alternatives for Obstructive Sleep Apnea (OSA) through
neuromodulation, today announced that the Company will participate
in the Piper Sandler 36th Annual Healthcare Conference
on Wednesday, December 4, 2024. The Company is scheduled to present
at 2:00pm ET the same day via webcast.
A live audio webcast of the presentation will be
available online at the investor relations page of the Company’s
website at investors.nyxoah.com.
About Nyxoah
Nyxoah is reinventing sleep for the billion people that suffer from
obstructive sleep apnea (OSA). We are a medical technology company
that develops breakthrough treatment alternatives for OSA through
neuromodulation. Our first innovation is Genio®, a battery-free
hypoglossal neuromodulation device that is inserted through a
single incision under the chin and controlled by a wearable.
Through our commitment to innovation and clinical evidence, we have
shown best-in-class outcomes for reducing OSA burden.
Following the successful completion of the BLAST
OSA study, the Genio® system received its European CE Mark in 2019.
Nyxoah completed two successful IPOs: on Euronext Brussels in
September 2020 and NASDAQ in July 2021. Following the positive
outcomes of the BETTER SLEEP study, Nyxoah received CE mark
approval for the expansion of its therapeutic indications to
Complete Concentric Collapse (CCC) patients, currently
contraindicated in competitors’ therapy. Additionally, the Company
announced positive outcomes from the DREAM IDE pivotal study for
FDA and U.S. commercialization approval.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
FORWARD-LOOKING STATEMENTS
Certain statements, beliefs and opinions in this
press release are forward-looking, reflecting Nyxoah's current
expectations and beliefs regarding the Genio® system; planned and
ongoing clinical studies of the Genio® system; the potential
advantages of the Genio® system; Nyxoah’s goals with respect to the
development, regulatory pathway and potential use of the Genio®
system; the utility of clinical data in potentially obtaining FDA
approval of the Genio® system; and potential receipt of FDA
approval and entrance into the U.S. market. By their nature,
forward-looking statements involve a number of risks,
uncertainties, assumptions and other factors that could cause
actual results or events to differ materially from those expressed
or implied by the forward-looking statements. These risks,
uncertainties, assumptions and factors could adversely affect the
outcome and financial effects of the plans and events described
herein. Additionally, these risks and uncertainties include, but
are not limited to, the risks and uncertainties set forth in the
“Risk Factors” section of Nyxoah’s Annual Report on Form 20-F for
the year ended December 31, 2023, filed with the Securities and
Exchange Commission (“SEC”) on March 20, 2024, and subsequent
reports that Nyxoah files with the SEC. A multitude of factors
including, but not limited to, changes in demand, competition and
technology, can cause actual events, performance or results to
differ significantly from any anticipated development. Forward
looking statements contained in this press release regarding past
trends or activities are not guarantees of future performance and
should not be taken as a representation that such trends or
activities will continue in the future. In addition, even if actual
results or developments are consistent with the forward-looking
statements contained in this press release, those results or
developments may not be indicative of results or developments in
future periods. No representations and warranties are made as to
the accuracy or fairness of such forward-looking statements. As a
result, Nyxoah expressly disclaims any obligation or undertaking to
release any updates or revisions to any forward-looking statements
in this press release as a result of any change in expectations or
any change in events, conditions, assumptions or circumstances on
which these forward-looking statements are based, except if
specifically required to do so by law or regulation. Neither Nyxoah
nor its advisers or representatives nor any of its subsidiary
undertakings or any such person's officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
Contacts:
Nyxoah
John Landry, CFO
IR@nyxoah.com
For Media
In United States
FINN Partners – Glenn Silver
glenn.silver@finnpartners.com
In Belgium/France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be
In International/Germany
MC Services – Anne Hennecke
nyxoah@mc-services.eu
- ENGLISH_NYXH Piper Conf Advisory PR
Nyxoah (EU:NYXH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Nyxoah (EU:NYXH)
Historical Stock Chart
From Dec 2023 to Dec 2024